VYNE
VYNE Therapeutics Inc.Company with tickers: VYNE
CIK
1566044
CUSIP
92941V308
Shares Outstanding
33,352,858
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $202,000 | USD | 2025-03-31 | 10-Q | 2026-05-15 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $6,124,000 | USD | 2025-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-9,197,000 | USD | 2025-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-8,611,000 | USD | 2025-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.20 | USD/shares | 2025-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.20 | USD/shares | 2025-03-31 | 10-Q | 2026-05-15 |